Vanguard Capital Management
ARTL icon

Vanguard Capital Management’s Artelo Biosciences ARTL Stock Holding History

Vanguard Capital Management’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Hold
10,129
– – ﹤0.01% 4046
2026
Q1 		$76.8K Buy
+10,129
New +$47.9K ﹤0.01% 3884

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Capital Management's ARTL Position: Q2 2026 in Review

Vanguard Capital Management held its Artelo Biosciences (ARTL) position steady in Q2 2026 at 10,129 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4046.

Vanguard Capital Management first reported a position in ARTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $76.8K in Q1 2026. 10 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • Vanguard Capital Management held 10,129 shares of Artelo Biosciences worth $11.3K as of Q2 2026.
  • Vanguard Capital Management left its Artelo Biosciences share count unchanged in Q2 2026.
  • Artelo Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4046 holding.
  • Vanguard Capital Management first reported a position in Artelo Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Artelo Biosciences position peaked at $76.8K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.